ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Iterum Therapeutics PLC

Iterum Therapeutics PLC (ITRM)

1.50
0.01
(0.67%)
Closed January 29 3:00PM
1.5009
0.0009
(0.06%)
After Hours: 6:47PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.5009
Bid
1.50
Ask
1.53
Volume
367,728
1.49 Day's Range 1.54
0.808 52 Week Range 3.02
Market Cap
Previous Close
1.49
Open
1.49
Last Trade
3
@
1.53
Last Trade Time
Financial Volume
US$ 556,658
VWAP
1.5138
Average Volume (3m)
1,056,019
Shares Outstanding
27,515,926
Dividend Yield
-
PE Ratio
-1.08
Earnings Per Share (EPS)
-1.39
Revenue
82k
Net Profit
-38.37M

About Iterum Therapeutics PLC

Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance ... Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Chicago, Illinois, USA
Founded
-
Iterum Therapeutics PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ITRM. The last closing price for Iterum Therapeutics was US$1.49. Over the last year, Iterum Therapeutics shares have traded in a share price range of US$ 0.808 to US$ 3.02.

Iterum Therapeutics currently has 27,515,926 shares outstanding. The market capitalization of Iterum Therapeutics is US$41 million. Iterum Therapeutics has a price to earnings ratio (PE ratio) of -1.08.

ITRM Latest News

Iterum Therapeutics Regains Full Nasdaq Compliance

DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat...

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

-- ORLYNVAHTM Approved by FDA on October 25, 2024โ€” --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0191-1.256578947371.521.57991.465003521.50335913CS
4-0.2791-15.67977528091.782.11.465563581.65877652CS
120.260921.04032258061.243.021.2110560191.91615071CS
260.270922.02439024391.233.020.80816527591.75258677CS
52-0.2091-12.22807017541.713.020.80810325371.70976759CS
1561.1712355.2320291170.32973.13050.1758748510.93807678CS
260-0.9991-39.9642.56.020.17536381641.35443862CS

ITRM - Frequently Asked Questions (FAQ)

What is the current Iterum Therapeutics share price?
The current share price of Iterum Therapeutics is US$ 1.5009
How many Iterum Therapeutics shares are in issue?
Iterum Therapeutics has 27,515,926 shares in issue
What is the market cap of Iterum Therapeutics?
The market capitalisation of Iterum Therapeutics is USD 41M
What is the 1 year trading range for Iterum Therapeutics share price?
Iterum Therapeutics has traded in the range of US$ 0.808 to US$ 3.02 during the past year
What is the PE ratio of Iterum Therapeutics?
The price to earnings ratio of Iterum Therapeutics is -1.08
What is the cash to sales ratio of Iterum Therapeutics?
The cash to sales ratio of Iterum Therapeutics is 500
What is the reporting currency for Iterum Therapeutics?
Iterum Therapeutics reports financial results in USD
What is the latest annual turnover for Iterum Therapeutics?
The latest annual turnover of Iterum Therapeutics is USD 82k
What is the latest annual profit for Iterum Therapeutics?
The latest annual profit of Iterum Therapeutics is USD -38.37M
What is the registered address of Iterum Therapeutics?
The registered address for Iterum Therapeutics is 200 S WACKER DRIVE, SUITE 650, CHICAGO, ILLINOIS, IL 60606
What is the Iterum Therapeutics website address?
The website address for Iterum Therapeutics is www.iterumtx.com
Which industry sector does Iterum Therapeutics operate in?
Iterum Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DGNXDiginex Ltd
US$ 49.18
(228.09%)
3.34M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
KRKR36Kr Holdings Inc
US$ 9.10
(114.12%)
23.61M
SPGCSacks Parente Golf Inc
US$ 0.6001
(57.92%)
52.17M
XFORX4 Pharmaceuticals Inc
US$ 0.7542
(56.54%)
42.49M
ZKINZK International Group Co Ltd
US$ 0.4813
(-41.21%)
3.1M
MGOLMGO Global Inc
US$ 0.1019
(-38.73%)
70.51M
BACKIMAC Holdings Inc
US$ 0.7869
(-35.50%)
2.37M
EYENEyenovia Inc
US$ 0.03695
(-35.18%)
25.31M
HAOHaoxi Health Technology Ltd
US$ 2.52
(-31.89%)
484.94k
NVDANVIDIA Corporation
US$ 123.70
(-4.10%)
466.93M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
OCEAOcean Biomedical Inc
US$ 0.249929
(-24.26%)
186.51M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.428
(-6.98%)
148.12M
RIMEAlgorhythm Holdings Inc
US$ 0.0259
(-16.18%)
138.96M

ITRM Discussion

View Posts
Klinsmann Klinsmann 2 months ago
Huh? Whatever you say... 
this stock is primed for a huge breakout soon. Chart beauty, and buyout news is just pending. They won't sell such a premium product for chump change. 
👍️ 1 🥳 1
KIPK KIPK 2 months ago
With EX pumping here ITRM will follow OTLK imo
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 2 months ago
100%! The approved drug is worth 300-500 million, and maybe this is even a conservative figure. Just look at the market cap and connect the dots... Have a nice weekend
👍️ 1 🤩 1
glenn1919 glenn1919 2 months ago
ITRM....................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
 just Scottie just Scottie 2 months ago
Ya think it can really go that high?
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 2 months ago
It depends. The fda approval makes this stock worth more than 10$. Not sure when book value and reality are going to match...
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
YEAH NO...BIT LATE SON EEARLY BIRD GETS THE WORM
๐Ÿ‘๏ธ0
madras50 madras50 2 months ago
there still time to jump on this or you think there is a pullback coming?
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
ITRM MONSTER
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
ITRM...................................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
ITRM BREAK OUT
👍 1
Klinsmann Klinsmann 2 months ago
I know! And that could mean 15-20$. But most donยดt even have the patience to hold until eow and are not able to stand a red day on the long way up and away...
๐Ÿ‘๏ธ0
exwannabe exwannabe 2 months ago
Not much patience needed. This will be likely be over before Spring.
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 2 months ago
This stock is going to really bust! Most don't have that needed patience...
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
ITRM GAPPING AS WE APPROACH BREAK OUT...PLAY WITH CAUTION
๐Ÿ‘๏ธ0
 just Scottie just Scottie 2 months ago
If Iโ€™m not in a stock it busts out
If Iโ€™m in it tanks is my usual scenario
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 2 months ago
In the end no matter what people on message boards say. The fundamentals in here are plain and simple great! I expect it to really astonish people soon - esp. when you're not in 😉
๐Ÿ‘๏ธ0
TrendTrade2016 TrendTrade2016 2 months ago
ITRM BREAK OUT PLAY FDA BIO MONTHS AGO
👍 1
exwannabe exwannabe 2 months ago
Huh? No need to pump! FDA approval is a given fact!
Just ignore KIPK.

He is pissed off on another stock (NWBO, where he is banned on this board) about my negative posts. So he follows me around like a stalker and posts idiotic comments on any stock I discuss.
👍️ 1
Klinsmann Klinsmann 2 months ago
Huh? No need to pump! FDA approval is a given fact!
๐Ÿ‘๏ธ0
KIPK KIPK 2 months ago
OTLK that EX been pumping just crashed; failed trial
๐Ÿ‘๏ธ0
KIPK KIPK 2 months ago
Beware of paid pumper/basher EX....................
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 2 months ago
But the final number gonna be 5-10 times above our market cap rn around 2$...
๐Ÿ‘๏ธ0
exwannabe exwannabe 2 months ago
The game plan is to monetize by selling off either rights to the drug or the company. Either way all is over and all we can do is wait on the final number.
๐Ÿ‘๏ธ0
 just Scottie just Scottie 2 months ago
Sounds about right my friend
👍️ 1
Klinsmann Klinsmann 2 months ago
Never left the boat! Added lows, no hurry to sell my shares. Expect 10$+
๐Ÿ‘๏ธ0
 just Scottie just Scottie 2 months ago
Where is everyone lol
A buyout is coming to town
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Very important drug. Big pharma like Pfizer may come calling or has called already
👍️ 1
Klinsmann Klinsmann 3 months ago
Gonna be a multi day run imo
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
ITRM..................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
👍 1 🚀 1
 just Scottie just Scottie 3 months ago
Excellent
👍 1 🚀 1
exwannabe exwannabe 3 months ago
Label is about as expected. They did recommend culture testing (to insure proper agent is used for specific bug), bt did so in a general way that implies it is universal. No black box (was mentioned as possible to warn against creating resistence).
👍 1 💯 1
tw0122 tw0122 3 months ago
Stuck in this halt but up 13% not  complaining 
1.40+ 20%
👍 1 🚀 1
 just Scottie just Scottie 3 months ago
Agree
👍 1 🔥 1
tw0122 tw0122 3 months ago
Big Pharma bribes, rules and runs the FDA its the American way of doing business meanwhiles urinary tract infection a big markets
👍 1 🚀 1
 just Scottie just Scottie 3 months ago
Any strength shown is met with selling
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Plus itโ€™s not right to tie the companyโ€™s hands and restrict their ability to sell a product which will actually help people by having specific instructions on labels.

I tend to think if this was a big company such as Merck or Pfizer we wouldnโ€™t have this issue
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Yes it sounds like there will be some stipulations the FDA will enact.
Itโ€™s a shame! I understand the bug resistance aspect being in the medical field tho.

Im still a believer in the MDโ€™S being the problem of which they donโ€™t want to take full responsibility.
The FDA shouldnโ€™t punish a biotech company for developing a new product which is needed. The AMA needs to do a better job of educating the educated 😆
๐Ÿ‘๏ธ0
exwannabe exwannabe 3 months ago
I went through the ADCOM material a few weeks ago, but mainly from the pov of understanding what the FDA analysis was. I am very comfortable the FDA is willing to bless sulo as being safe and effective, the only open question is how to try to restrict use to avoid resistance.

Replaying it and listening more closely to the details of the discussion of creating resistance, I can understand how this is a tough issue to tackle.

The proposed label by ITRM (designated susceptible micro-organisms) is clearly a non-starter. Nobody at the ADCOM could even say what that means, and even if they could, the family doc is not about to call for a several hundred dollar test just to prescribe a cheap pill that almost always "works". Alternatives such as use after failure or use for resistant bugs had no supportable data,. Certainly a problem for the FDA, but they will find some label that expresses the concern.

I would be certain they will exclude use as a step down following IV treatments. I suspect they will somehow say use for cases where the doctor finds treatment via augmenten is not suitable.

I would not at all be surprised to see the FDA go off the farm and issue a black box against abuse due to risk of generating carbo-penum resistant bugs.

I wold be certain there will be a REMS and/or post approval study on these issues.

On the broader issue of antibiotic management, I was encouraged everybody took it seriously. I was discouraged that most all felt the community docs will broadly ignore it and take the easy way out.

.
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Yes! Cipro and augmentin have been around for a long time.
It will take a while for the bugs to become resistant to this one.
And yes the doctors are the ones that caused this over prescribing. They give it away like candy and use it as a prophylactic after just about every surgery
๐Ÿ‘๏ธ0
exwannabe exwannabe 3 months ago
For some explanation on that subject, the absurd off-label use of all antibiotics is a huge issue. That is true for all, nothing specific here. Go to most any third world or developing country and you can buy Cirpro for a few bucks for 2 weeks(?) worth, no prescription.

This is what is causing the problem with "super bugs". So yes, the FDA has a concern here.

OTOH, the same thing is why we need more choice in the field of antibiotics. And that is what this is, another choice for bugs that are are resistent to other antibiotics.
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
AI Overview
According to recent updates, the FDA appears to be leaning towards approving Sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs), but with significant concerns regarding antimicrobial resistance and the need for careful monitoring through post-marketing surveillance to ensure appropriate usage; the FDA Advisory Committee acknowledged the potential benefit for a subset of patients while emphasizing the importance of managing off-label use and potential impact on antimicrobial resistance if approved.
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Sounds like the drug works well. FDA has to have the appropriate usage on the label it sounds like
๐Ÿ‘๏ธ0
exwannabe exwannabe 3 months ago
Odds of approval are high, but I would not expect a huge gain.

Maybe up to $2-3 on thumbs up. Certainly down to almost $0 on thumbs down.

Again, I think the odds are good, so a good bet. Just think this is not one of those huge jumps you see on some drug approvals.
๐Ÿ‘๏ธ0
 just Scottie just Scottie 3 months ago
Any believers their drug gets approved Oct 25th?
Should fly if it does
๐Ÿ‘๏ธ0
cervelo cervelo 4 months ago
dang it should have run right after you sold
๐Ÿ‘๏ธ0
velcro velcro 6 months ago
No update or feedback, I dumped all shares
๐Ÿ‘๏ธ0
velcro velcro 6 months ago
Anyone understand the strategic planning behind the dilutive prospectus?
ITRM wants to raise cash now in the event the NDA Hearing is not good?
Or ITRM wants to raise cash now to hit the ground running with advertising after the successful NDA Hearing(s) in Sept and Oct.?
One indicator will be after subscription rights end 5 PM on August 6. Did investors jump on this or luke-warm maybe?
๐Ÿ‘๏ธ0
velcro velcro 8 months ago
Good News https://www.iterumtx.com/news/press-releases/detail/124/iterum-therapeutics-receives-fda-acceptance-of-resubmission
๐Ÿ‘๏ธ0
glenn1919 glenn1919 8 months ago
ITRM.......................https://stockcharts.com/h-sc/ui?s=ITRM&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock